一种新型蛋白基肺炎球菌疫苗对婴儿肺炎链球菌鼻咽携带的效力:一项2期、随机、对照、观察者盲法研究
在冈比亚1200名8-10周龄健康婴儿中开展的2期随机对照观察者盲法试验,评估含肺炎球菌蛋白的PHiD-CV/dPly/PhtD疫苗对非10VT肺炎球菌鼻咽携带的影响。结果显示,无论蛋白剂量或接种程序,试验疫苗对非10VT鼻咽携带均无影响,效力分别为1.1%(95%CI -21.5, 19.5)和2.1%(-20.3, 20.3)及0.5%(-22.1, 18.9)。
要点
- 在鼻咽携带高流行背景下,含肺炎球菌蛋白的试验疫苗对婴儿肺炎球菌鼻咽携带无影响。
- PHiD-CV/dPly/PhtD-10和PHiD-CV/dPly/PhtD-30对非10VT携带的效力分别为1.1%和2.1%,均无统计学意义。
- 两种蛋白基疫苗均诱导了对肺炎球菌蛋白的免疫应答,但未观察到携带获得、清除或细菌载量的差异。
核心结论
- 在高携带率背景下,将肺炎球菌蛋白纳入PHiD-CV/dPly/PhtD试验疫苗对婴儿肺炎球菌鼻咽携带无影响,无论蛋白剂量或接种程序。
研究设计与样本
- 2期、随机、对照、观察者盲法试验,在冈比亚 peri-urban 健康中心招募8-10周龄健康婴儿,按1:1:1:1:1:1随机分为六组。
- 四组在2-3-4月龄接种3+0程序:PHiD-CV/dPly/PhtD(每种蛋白10或30μg)、PHiD-CV或13价肺炎球菌结合疫苗;两组在2-4-9月龄接种2+1程序:PHiD-CV/dPly/PhtD-30或PHiD-CV。
- 共入组1200名婴儿,招募时间为2011年6月至2012年5月。
主要发现
- 基线时肺炎球菌携带率为60-67%,非10VT携带率为55-61%。
- 3+0程序中,PHiD-CV/dPly/PhtD-10和PHiD-CV/dPly/PhtD-30对非10VT鼻咽携带的效力分别为1.1%(95% CI -21.5, 19.5)和2.1%(95% CI -20.3, 20.3)。
- 2+1程序中,PHiD-CV/dPly/PhtD-30相比PHiD-CV对非10VT鼻咽携带的效力为0.5%(95% CI -22.1, 18.9)。
- 未观察到肺炎球菌鼻咽携带获得、清除或细菌载量的差异。
- 两种蛋白基疫苗均诱导了对肺炎球菌蛋白的免疫应答。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Conserved pneumococcal proteins are potential candidates for inclusion in vaccines against pneumococcal diseases. In the first part of a two-part study, an investigational vaccine (PHiD-CV/dPly/PhtD-30) containing 10 pneumococcal serotype-specific polysaccharide conjugates (10VT) combined with pneumolysin toxoid and pneumococcal histidine triad protein D (30μg each) was well tolerated by Gambian children. Part two, presented here, assessed the efficacy of two PHiD-CV/dPly/PhtD formulations against pneumococcal nasopharyngeal carriage (NPC) prevalence in infants. METHODS: In this phase 2, randomized, controlled, observer-blind trial, healthy infants aged 8-10weeks, recruited from a peri-urban health center, were randomized (1:1:1:1:1:1) into six groups. Four groups received PHiD-CV/dPly/PhtD (10 or 30μg of each protein), PHiD-CV, or 13-valent pneumococcal conjugate vaccine at ages 2-3-4months (3+0 infant schedule) and two groups PHiD-CV/dPly/PhtD-30 or PHiD-CV at 2-4-9months (2+1 infant schedule). The primary objective was impact on non-10VT NPC at ages 5-9-12months. Secondary objectives included confirmatory analysis of protein dose superiority and safety/reactogenicity. Impact on pneumococcal NPC acquisition, bacterial load, and ply and phtD gene sequencing were explored. RESULTS: 1200 infants were enrolled between June 2011 and May 2012. Prevalences of pneumococcal (60-67%) and non-10VT (55-61%) NPC were high at baseline. Across all post-vaccination time points, efficacy of PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 against non-10VT NPC (3+0 schedule) was 1.1% (95% CI -21.5, 19.5) and 2.1% (-20.3, 20.3), respectively; efficacy of PHiD-CV/dPly/PhtD-30 (2+1 schedule) was 0.5% (-22.1, 18.9) versus PHiD-CV. No differences were observed in pneumococcal NPC acquisition, clearance, or bacterial load. Both protein-based vaccines elicited immune responses to pneumococcal proteins. CONCLUSIONS: In this high carriage prevalence setting, inclusion of pneumococcal proteins in the PHiD-CV/dPly/PhtD investigational vaccine had no impact on pneumococcal NPC in infants, regardless of protein dose or schedule. Future evaluations will assess its impact against pneumococcal disease endpoints. FUNDING: PATH, GlaxoSmithKline Biologicals SA. ClinicalTrials.gov identifier NCT01262872.
引用
- Odutola A, Ota MOC, Antonio M, et al. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study. Vaccine. 2017. PMID: 28389097. doi:10.1016/j.vaccine.2017.03.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。